Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects

Journal of Clinical Pharmacology

Volumn 52, Issue 3, 2012, Pages 319-328

  Chen, Dawn ^a   Whitcomb, Randall ^a   MacIntyre, Euan ^a   Tran, Vinh ^a   Do, Zung N ^a   Sabry, James ^a   Patel, Dinesh V ^a   Anandan, Sampath K ^a   Gless, Richard ^a   Webb, Heather K ^b  

^a Arete Therapeutics Inc   (United States)

^b Calistoga Pharmaceuticals   (United States)

Author keywords

AR9281; eicosanoids; pharmacodynamics; pharmacokinetics; soluble epoxide hydrolase inhibitor

Indexed keywords

AR 9281; C REACTIVE PROTEIN; CREATINE KINASE; ENZYME INHIBITOR; EPOXIDE HYDROLASE; INTERLEUKIN 6; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; MUSCULOSKELETAL PAIN; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADAMANTANE; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EPOXIDE HYDROLASES; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; UREA; YOUNG ADULT;

EID: 84860185460     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010397049     Document Type: Article

References (25)

1. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009 ; 8: 794-805
2. Marino JP. Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery. Curr Top Med Chem. 2009 ; 9: 452-463
3. Luo P, Chang HH, Zhou Y, et al. Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther. 2010 ; 334: 430-438
4. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem. 2000 ; 275: 40504-40510
5. Enayetallah AE, French RA, Thibodeau MS, Grant DF. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem. 2004 ; 52: 447-454
6. Seidegård J, DePierre JW, Pero RW. Measurement and characterization of membrane-bound and soluble epoxide hydrolase activities in resting mononuclear leukocytes from human blood. Cancer Res. 1984 ; 44: 3654-3660
7. Jiang H, Zhu AG, Mamczur M, Morisseau C, Hammock BD, Falck JR, McGiff JC. Hydrolysis of cis- and trans-epoxyeicosatrienoic acids by rat red blood cells. J Pharmacol Exp Ther. 2008 ; 326: 330-337
8. Morisseau C, Hammock BD. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol. 2005 ; 45: 311-333
9. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 2002 ; 39: 690-694
10. Imig JD, Zhao X, Zaharis , et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension. 2005 ; 46: 975-981
11. Xu D, Li N, He Y, et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A. 2006 ; 103: 18733-18738
12. Motoki A, Merkel MJ, Packwood WH, et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am J Physiol Heart Circ Physiol. 2008 ; 295: H2128 - H2134
13. Simpkins AN, Rudic RD, Schreihofer DA, et al. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol. 2009 ; 174: 2086-2095
14. Ulu A, Cavis BB, Tsai HJ, et al. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J Cardiovasc Pharmacol. 2008 ; 52: 314-323
15. Sodhi K, Inoue K, Gotlinger KH, et al. Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. J Pharmacol Exp Ther. 2009 ; 331: 906-916
16. Manhiani M, Quigley JE, Knight SF, et al. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol. 2009 ; 297: F740 - F748
17. Seubert JM, Sinal CJ, Graves J, et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res. 2006 ; 99: 442-450
18. Zhang W, Otsuka T, Sugo N, et al. Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. Stroke. 2008 ; 39: 2073-2078
19. Inceoglu B, Jinks SL, Schmelzer KR, Waite T, Kim IH, Hammock BD. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci. 2006 ; 79: 2311-2319
20. Whitcomb R, Chen D, Wang Y-X, Anandam S-K, Gless R, Webb HK. AR9281, a soluble epoxide hydrolase inhibitor-efficacy in a DIO mouse model plus pharmacokinetics and pharmacodynamics in mice and men. Diabetes. 2009 ; 58 (suppl 1). A165
21. Imig JD, Carpenter MA, Shaw S. The soluble epoxide hydrolase inhibitor AR9281 decreases blood pressure, ameliorates renal injury and improves vascular function in hypertension. Pharmaceuticals. 2009 ; 2: 217-227
22. Wong K, Zhang L-N, Vincelette J, et al. A novel inhibitor of soluble epoxide hydrolase, AR9281, improves glucose homeostasis in diet-induced obese mice. Diabetes. 2009 ; 58 (suppl 1). A436
23. Dixon M. The graphical determination of Km and Ki. Biochem J. 1972 ; 129: 197-202
24. Kim IH, Tsai HJ, Nishi K, Kasagami T, Morisseau C, Hammock BD. 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties. J Med Chem. 2007 ; 50: 5217-5226
25. A randomized, double-blind, placebo-controlled, dose- ranging, exploratory, 28-day study to examine the effects of AR9281 on blood pressure and glucose tolerance in patients with mild to moderate hypertension and impaired glucose tolerance. ClinicalTrials.gov. :